• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Zai Lab Limited

    8/12/25 4:45:11 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZLAB alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001731790
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Zai Lab Ltd
    SEC File Number
    001-38205
    Address of Issuer
    4560 JINKE ROAD
    BLDG. 1, 4F, PUDONG
    SHANGHAI
    CHINA
    201203
    Phone
    862161632588
    Name of Person for Whose Account the Securities are To Be Sold
    Du Ying
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer
    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    American Depositary Shares
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    500001712555.5342172545008/12/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    American Depositary Shares08/12/2025Option Granted - 10/22/2015IssuerCheckbox not checked5000008/12/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Ying Du
    899 Halei Road
    Building B, Pudong
    Shanghai � F4 � 201203
    American Depositary Shares05/12/2025500001472165.00
    Ying Du
    899 Halei Road
    Building B, Pudong
    Shanghai � F4 � 201203
    American Depositary Shares05/13/2025500001428650.00
    Ying Du
    899 Halei Road
    Building B, Pudong
    Shanghai � F4 � 201203
    American Depositary Shares05/14/2025463891302858.26
    Ying Du
    899 Halei Road
    Building B, Pudong
    Shanghai � F4 � 201203
    American Depositary Shares06/26/202523669855196.47
    Ying Du
    899 Halei Road
    Building B, Pudong
    Shanghai � F4 � 201203
    American Depositary Shares06/30/20256918245723.90
    Ying Du
    899 Halei Road
    Building B, Pudong
    Shanghai � F4 � 201203
    American Depositary Shares07/02/20257072249143.73
    Ying Du
    899 Halei Road
    Building B, Pudong
    Shanghai � F4 � 201203
    American Depositary Shares08/08/2025500001737155.00
    Ying Du
    899 Halei Road
    Building B, Pudong
    Shanghai � F4 � 201203
    American Depositary Shares08/11/2025500001731815.00

    144: Remarks and Signature

    Remarks
    Date of Notice
    08/12/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    11/20/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Joshua Schmitt, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Ying Du.

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $ZLAB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZLAB

    DatePrice TargetRatingAnalyst
    3/7/2025$55.00Sector Outperform
    Scotiabank
    3/3/2025$29.00 → $36.10Buy → Neutral
    BofA Securities
    12/14/2023$47.50Overweight
    Morgan Stanley
    8/10/2023$70.00Overweight
    Cantor Fitzgerald
    3/2/2022$194.00 → $102.00Outperform
    SVB Leerink
    1/21/2022$64.00Outperform
    Macquarie
    12/15/2021$189.00 → $136.00Overweight
    JP Morgan
    11/11/2021$222.00 → $217.00Buy
    Citigroup
    More analyst ratings

    $ZLAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Scotiabank initiated coverage on Zai Lab with a new price target

    Scotiabank initiated coverage of Zai Lab with a rating of Sector Outperform and set a new price target of $55.00

    3/7/25 8:00:31 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zai Lab downgraded by BofA Securities with a new price target

    BofA Securities downgraded Zai Lab from Buy to Neutral and set a new price target of $36.10 from $29.00 previously

    3/3/25 7:38:45 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Zai Lab with a new price target

    Morgan Stanley initiated coverage of Zai Lab with a rating of Overweight and set a new price target of $47.50

    12/14/23 7:54:36 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZLAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer

    Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that the China National Medical Products Administration (NMPA) has granted Innovative Medical Device Designation for Tumor Treating Fields (TTFields) for patients with pancreatic cancer based on the positive results from the Phase 3 PANOVA-3 trial. The Innovative Medical Device Designation allows Zai Lab to take advantage of an expedited approval procedure for TTFields that offers opportunities for the NMPA to prioritize the allocation of review resources to expedite the regulatory review and approval process. "We are excited that TTFields has been granted the Innovative Medical Device Designation, a status that offers expedited r

    8/19/25 7:30:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zai Lab Establishes Oncology Scientific Advisory Board

    - Newly formed Advisory Board comprises world-class leaders in oncology to support advancement of Zai Lab's robust oncology products and pipeline Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced the creation of its Oncology Scientific Advisory Board (SAB). The newly formed Oncology SAB is comprised of distinguished oncology leaders and will support the advancement of the Company's robust oncology products and pipeline, including multiple internally developed investigational therapies. "We are honored to bring together this esteemed group of oncology leaders who will support our continued development and advancement of innovative treatment options for patients globally," said R

    8/13/25 11:00:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates

    Total revenues grew 9% y-o-y to $110.0 million for the second quarter of 2025; reaffirming full-year 2025 revenue guidance of $560 million to $590 million VYVGART reached record patient utilization in the second quarter; updated national guidelines elevate VYVGART's role as a treatment for both acute and maintenance gMG Operating loss improved by 28% year-over-year to $54.9 million for the second quarter of 2025, and by 37% to $34.2 million on an adjusted basis1; on track to achieve profitability1 in the fourth quarter of 2025 ZL-1310 (DLL3 ADC) data presented at ASCO 2025 showed a 67% ORR across all doses (n=33) and 79% at 1.6mg/kg (n=14) in 2L ES-SCLC, with a differentiate

    8/7/25 6:00:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZLAB
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Zai Lab Limited

    SCHEDULE 13G - Zai Lab Ltd (0001704292) (Subject)

    8/14/25 8:14:51 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Zai Lab Limited

    144 - Zai Lab Ltd (0001704292) (Subject)

    8/12/25 4:45:11 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Zai Lab Limited

    SCHEDULE 13G/A - Zai Lab Ltd (0001704292) (Subject)

    8/12/25 10:34:26 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZLAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Smiley Joshua L bought $64,200 worth of American Depositary Shares (3,000 units at $21.40), increasing direct ownership by 10% to 31,684 units (SEC Form 4)

    4 - Zai Lab Ltd (0001704292) (Issuer)

    5/15/24 4:03:12 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Smiley Joshua L bought $62,490 worth of American Depositary Shares (3,000 units at $20.83), increasing direct ownership by 15% to 23,527 units (SEC Form 4)

    4 - Zai Lab Ltd (0001704292) (Issuer)

    3/4/24 4:28:34 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Smiley Joshua L bought $119,600 worth of American Depositary Shares (4,000 units at $29.90), increasing direct ownership by 24% to 20,527 units (SEC Form 4)

    4 - Zai Lab Ltd (0001704292) (Issuer)

    12/18/23 5:08:48 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZLAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Chen Yajing converted options into 1,250 units of American Depositary Shares and sold $50,932 worth of American Depositary Shares (1,438 units at $35.42), decreasing direct ownership by 1% to 16,720 units (SEC Form 4)

    4 - Zai Lab Ltd (0001704292) (Issuer)

    8/18/25 4:29:46 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairperson & CEO Du Ying exercised 96,387 units of American Depositary Shares at a strike of $0.60 and sold $3,357,842 worth of American Depositary Shares (96,387 units at $34.84) (SEC Form 4)

    4 - Zai Lab Ltd (0001704292) (Issuer)

    8/14/25 5:22:43 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Amado Rafael sold $105,000 worth of American Depositary Shares (3,000 units at $35.00), decreasing direct ownership by 7% to 42,178 units (SEC Form 4)

    4 - Zai Lab Ltd (0001704292) (Issuer)

    8/12/25 4:45:52 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZLAB
    Financials

    Live finance-specific insights

    View All

    Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates

    Total revenues grew 9% y-o-y to $110.0 million for the second quarter of 2025; reaffirming full-year 2025 revenue guidance of $560 million to $590 million VYVGART reached record patient utilization in the second quarter; updated national guidelines elevate VYVGART's role as a treatment for both acute and maintenance gMG Operating loss improved by 28% year-over-year to $54.9 million for the second quarter of 2025, and by 37% to $34.2 million on an adjusted basis1; on track to achieve profitability1 in the fourth quarter of 2025 ZL-1310 (DLL3 ADC) data presented at ASCO 2025 showed a 67% ORR across all doses (n=33) and 79% at 1.6mg/kg (n=14) in 2L ES-SCLC, with a differentiate

    8/7/25 6:00:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025

    - Company to host conference call and webcast on August 7, 2025, at 8:00 a.m. ET (8:00 p.m. HKT) Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that it will report its second quarter 2025 financial results and provide recent corporate updates on August 7, 2025, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT). Conference Call and Webcast Information Listeners may access the live webcast by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows: Registration link for webcast (preferred):

    7/10/25 7:30:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

    - Clinically meaningful anti-tumor activity of ZL-1310 observed in heavily pretreated population of patients with small cell lung cancer (SCLC) across dose escalation and expansion cohorts - In second-line (2L) SCLC, objective response rate (ORR) was 67% across all dose levels (n=33) and 79% at 1.6 mg/kg dose (n=14) - Median duration of response has not yet been reached, with 29 of 38 responders remaining on study; 27 of 31 patients with stable disease remaining on study, the majority of whom had tumor regressions - ZL-1310 demonstrated a well-tolerated safety profile at target doses of less than 2.0 mg/kg, with Grade ≥3 treatment-related adverse events (TRAEs) of 6%, and no drug disc

    6/2/25 7:00:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZLAB
    Leadership Updates

    Live Leadership Updates

    View All

    Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

      Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases (NSAiID) of Zai Lab, will retire at the end of June, after which he will serve as a senior advisor for the Company. Rafael Amado, M.D., President, Head of Global Oncology Research and Development of Zai Lab, will expand his role and assume responsibility for all of the Company's Global R&D upon Dr. Reinhart's retirement. "Harald has devoted nearly 50 years to treating patients, first as a physician and later discovering and developing innovative therapies to bring to patients in

    6/11/24 4:05:00 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zai Lab Appoints Michel Vounatsos To Its Board of Directors

    SHANGHAI and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that Michel Vounatsos has been appointed to its Board of Directors, effective January 7, 2023. Mr. Vounatsos brings to the Board extensive global leadership and management experience in the biopharmaceutical industry, including more than 25 years of service at leading companies. His expertise includes significant commercial experience in China and worldwide in the areas of primary care and neuroscience. "We are delighted to welcome Michel Vounatsos to the Zai Lab Board of Directors," said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. "Michel has a wealt

    1/9/23 7:30:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

    SHANGHAI and CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the appointment of Rafael G. Amado, M.D. as President, Head of Global Oncology Research and Development, effective December 30, 2022. Dr. Amado brings to Zai Lab deep expertise in the field of oncology and significant global biopharmaceutical R&D leadership. "We are pleased to welcome Rafael to our executive leadership team," said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. "Rafael's experience leading worldwide discovery and clinical development for a number of oncolog

    1/3/23 8:30:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZLAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Zai Lab Limited

    SC 13G - Zai Lab Ltd (0001704292) (Subject)

    11/14/24 11:11:39 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zai Lab Limited

    SC 13G/A - Zai Lab Ltd (0001704292) (Subject)

    11/8/24 10:52:38 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Zai Lab Limited (Amendment)

    SC 13G/A - Zai Lab Ltd (0001704292) (Subject)

    6/6/24 9:54:34 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care